Shares of the weight-loss giant Novo Nordisk A/S (NYSE:NVO) are plunging by over 6% during Wednesday morning trading in New York, in response to the quarterly results released during the premarket. What Happened: Novo Nordisk reported second-quarter 2024 sales of DKK 68.06 billion ($9.972 billion), which fell slightly short of the Wall Street analysts’ consensus of DKK 68.66 billion ($.99 billion). The strength in the insulin portfolio was able to compensate for the sales shortfalls in Ozempic and Wegovy, as well as the weaknesses in the rare disease portfolio. Notably, sales of the weight-loss blockbuster Wegovy were 14% below consensus estimates. Earnings per share (EPS) also fell short of analyst expectations, reporting DKK 4.49 (USD 0.658) compared to the expected DKK ...